Metropolis Healthcare to acquire Dehradun's Leading Diagnostic Chain, Dr. Ahujas' Pathology & Imaging Centre

Ameera Shah-led Metropolis Healthcare Limited (NSE: METROPOLIS | BSE: 542650), India's second-largest and most respected pathology laboratory chain, today announced that its wholly owned subsidiary, Metropolis Histoxpert Digital Services Private Limited, has entered into a business transfer agreement to acquire Dehradun's leading diagnostic chain - Dr. Ahujas' Pathology and Imaging Centre (DAPIC).

Founded in 1990 by Dr. Alok Ahuja and Dr. Alka Ahuja, DAPIC has established itself as a trusted name in Uttarakhand's diagnostic sector, known for its high standards of quality and accuracy. The organization operates two laboratories accredited by NABL and NABH, 11 patient service centres, and nine hospital-based centres. It offers a comprehensive range of pathology and soft radiology services, including ultrasound, ECG, and X-ray. In FY 2024-25, DAPIC recorded an estimated annual revenue of INR 11.5 crore (unaudited*), with pathology services contributing 73% and radiology services 27%. With 80 percent of its revenue coming from walk-in patients, the chain has built a strong B2C presence, making it a valuable addition to Metropolis' growing network in North India.

Under the agreement, Metropolis' wholly owned subsidiary Metropolis Histoxpert Digital Services Private Limited, will acquire 100% ownership of DAPIC in an all-cash deal valued at INR 35.01 crores. To ensure a seamless transition, Dr. Alok Ahuja and Dr. Alka Ahuja will continue their association with the business postacquisition.

Commenting on the acquisition, Ms. Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Limited, said: "Dr. Ahujas' Pathology & Imaging Centre has established a strong reputation for high-quality B2C services, scientific excellence, and patient trust, making it an ideal addition to Metropolis' growth strategy. Together with the acquisition of Core Diagnostics, a leader in oncology testing, Scientific Pathology, the dominant chain in Agra, and now DAPIC, the leading diagnostic chain in Dehradun, we are further strengthening our 'String of Pearls' strategy-aimed at building a robust and regionally diverse diagnostic network across North India. These strategic moves have expanded the North India contribution to our overall revenues from 8% to an estimated 14-15%. Building on this momentum, we aim to accelerate our expansion across Uttar Pradesh and Uttarakhand-two high-growth markets with significant potential. We are delighted to welcome Dr. Alok Ahuja and Dr. Alka Ahuja into the Metropolis family as we integrate DAPIC to further enhance patient care."

Mr. Surendran Chemmenkotil, Chief Executive Officer, Metropolis Healthcare Limited, said: "Uttarakhand is one of the fastest-growing diagnostic markets in North India, valued at approximately INR 500 crore. This acquisition strengthens our presence, expanding access to high-quality diagnostics while deepening engagement with doctors and patients. With the combined strength of DAPIC's established network of labs and centres and Metropolis' existing laboratory and six centres in Dehradun, we are now the second-largest diagnostic chain in Uttarakhand. This integration will enhance both B2B and B2C reach with a comprehensive test portfolio, including specialized diagnostics. Furthermore, we will expand accessibility through a structured franchise model, reinforcing our commitment to scientific excellence and superior healthcare delivery."

Dr. Alok Ahuja, Founder of Dr. Ahujas' Pathology & Imaging Centre, said: "Metropolis Healthcare is one of the most respected diagnostic chains in India, synonymous with quality, scientific expertise, and patient trust. This partnership marks the perfect alignment for DAPIC's next phase of growth. Our team has earned the trust of both the medical fraternity and the public in Uttarakhand, and we believe this collaboration will further elevate service standards and accessibility. With Metropolis' advanced testing capabilities and strong brand recognition, we are confident of driving meaningful growth and innovation in the region-while preserving the legacy of excellence that DAPIC is known for."

EY was the exclusive financial adviser to DAPIC and BDO India LLP acted as the financial advisor to Metropolis Healthcare Limited.

Shares of Metropolis Healthcare Limited was last trading in BSE at Rs. 1550.20 as compared to the previous close of Rs. 1583.80. The total number of shares traded during the day was 4829 in over 626 trades.

The stock hit an intraday high of Rs. 1571.40 and intraday low of 1539.00. The net turnover during the day was Rs. 7531702.00.

Source : Equity Bulls

Keywords

MetropolisHealthcare INE112L01020 MetropolisHistoxpertDigitalServices Acquisition DrAhujasPathologyandImagingCentre Dehradun